Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 19, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is a transaction by Mr. R Bondy, who acquired a beneficial interest in 1 Ordinary Share. The share was purchased under a Personal Equity Plan on December 18, 2006, at a price of GBP 13.37.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details the share acquisition in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the identity of Mr. R Bondy and his role within GlaxoSmithKline plc.
- Confirm the transaction date of December 18, 2006, and the purchase price of GBP 13.37 per share.
- Note that this filing does not reflect broader company financial performance or strategic changes.